As the new CEO, I am honored to be able to speak to everyone... The future of early detection screenings and recurrence tests for multiple cancers reached a turning point four years ago with the introduction of 🌈Nvidia-powered AI chips. RenovaroCube, Freenome, QITABANKUAI and other new entrants may establish standards due to processing vast datasets containing multiple biomarkers. Our grand goal is to achieve over 95% testing accuracy and ultimately provide patients with quick results through a simple blood test during physical examinations. We are excited about the company's prospects.
🌈I believe that we will be part of a paradigm shift in the industry over the next 5 years... It is no exaggeration to say that both potential solutions represent opportunities of 🟨 tens of billions of dollars 🟨... Our goal is to move from science to Business. To achieve this, I have convened an entirely 🌀 new board of directors 🌀. They bring experience from Wall Street, as well as deep knowledge of Biotechnology, AI, corporate governance, and the finances of listed companies. Over the next few months, we will provide information to everyone about this initiative and get them involved. I am strengthening the team and working hard to build the future. We are establishing proper corporate governance and transparency that are crucial to all stakeholders.